FRANKLIN, Ohio, Jan. 15, 2014 /PRNewswire/ -- A novel wearable injector slightly larger than an Oreo cookie may soon make it easy and painless for patients to self-inject prescription drugs in the large doses required to treat a wide range of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.
An emerging biologic drugs market is expected to grow to $220B by 2018, according to analysts. Many of these drugs will require a new type of injector that does not exist today for self-administration of high volumes and high viscosities.
Mike Hooven, Enable Injections LLC's founder and CEO, will present a new drug delivery technology that addresses these needs to pharmaceutical executives at two meetings this month:
"Having an injector like this, especially one that decreases pain, opens the door to new pharmaceuticals that wouldn't be possible without this revolutionary device," says Gary Ansel, MD, Associate Medical Director of the OhioHealth Research and Innovation Institute in Columbus. "We're talking potential for huge cost savings, reduced hospital stays, and increased patient compliance—all at the push of a button."
Currently available for investigational use only, Enable's bolus injector uses standard vials, can automatically mix powdered/liquid vials, and may deliver doses as large as 20cc. Patients would wear the disposable device under their clothing and comfortably go about their business during the infusion.
"Enable has a world-class design team that has developed a unique technology to address this exciting new opportunity. We're looking forward to working with our pharmaceutical partners to introduce these products to market," says Hooven, a medical device veteran who previously founded AtriCure, the first device company to obtain FDA clearance for the surgical treatment of atrial fibrillation.
About Enable Injections
Enable Injections, LLC develops wearable bolus injectors for investigational use in the pharmaceutical and biotechnology industries to deliver high viscosity, high volume payloads up to 20cc to the subcutaneous tissue. The system uses a standard vial container closure, and can automatically mix lyophilized solutions. Founded February 2010 by medical device industry veterans, the company has R&D and manufacturing facilities in Franklin, Ohio.
|SOURCE Enable Injections, LLC|
Copyright©2012 PR Newswire.
All rights reserved